We are live on
!
Find out more
TCM
Tang Capital Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
125.1%
This Fund
S&P 500
This Quarter
Est. Return
-3.23%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$502M
AUM Growth
+$147M
(+41%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
33.03%
Top 10 Holdings %
Top 10 Hldgs %
94.84%
Holding
17
New
6
Increased
2
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Heron Therapeutics
HRTX
|
+$126M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$12.3M |
| 3 |
Altimmune
ALT
|
+$10.7M |
| 4 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
+$8.08M |
| 5 |
RVPH
REVIVA PHARMA HLDGS INC
RVPH
|
+$6.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VINCW
Vincerx Pharma, Inc. Warrant
VINCW
|
+$4.1M |
| 2 |
Relmada Therapeutics
RLMD
|
+$3.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Heron Therapeutics
HRTX
$86.3M
| $123M | 24.43% |
+7,907,087
| New | +$126M |
|
2
Rocket Pharmaceuticals
RCKT
$348M
| $112M | 22.32% |
2,531,800
| – | – |
|
3
AnaptysBio
ANAB
$1.6B
| $68.2M | 13.57% |
2,628,678
| – | – |
|
|
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $54.1M | 10.78% |
15,514,566
| – | – |
|
|
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $43M | 8.56% |
10,049,224
+643,734
| +7% | +$2.76M |
|
6
Aptevo Therapeutics
APVO
$5.47M
| $39.5M | 7.86% |
3
| – | – |
|
|
VINC
7
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $13.4M | 2.66% |
51,532
+26,532
| +106% | +$8.08M |
|
8
Coherus Oncology
CHRS
$217M
| $8.99M | 1.79% |
650,000
| – | – |
|
|
9
Altimmune
ALT
$539M
| $7.72M | 1.54% |
+783,407
| New | +$10.7M |
|
|
CCXI
10
DELISTED
ChemoCentryx, Inc.
CCXI
| $6.7M | 1.33% |
+500,000
| New | +$12.3M |
|
|
RVPH
11
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $5.83M | 1.16% |
+60,000
| New | +$6.05M |
|
|
ITOS
12
DELISTED
iTeos Therapeutics
ITOS
| $5.63M | 1.12% |
+219,396
| New | +$5.23M |
|
13
Tango Therapeutics
TNGX
$4.34B
| $5.33M | 1.06% |
468,750
| – | – |
|
14
Equillium
EQ
$157M
| $3.53M | 0.7% |
600,000
| – | – |
|
|
15
Relmada Therapeutics
RLMD
$544M
| $3.2M | 0.64% |
100,000
-100,000
| -50% | -$3.47M |
|
16
NextCure
NXTC
$17.3M
| $2.41M | 0.48% |
+25,000
| New | +$2.56M |
|
|
VINCW
17
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
| – | – |
-1,014,368
| Closed | -$4.1M |
|
Similar funds
HA
SGAM
CCA
FWTB
NIM
RMCM
FC
SC
Tang Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Tang Capital Management held 17 positions worth $502M, up 41% from $355M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Tang Capital Management deployed $166M of net new capital in Q2 2021, opening 6 new positions and adding to 2 existing holdings. Its largest new stake was Heron Therapeutics: 7,907,087 shares worth $123M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.
On the sell side, the largest reduction was Relmada Therapeutics, an estimated $3.47M trimmed.
- Tang Capital Management's largest Q2 2021 buy was Heron Therapeutics: 7,907,087 shares worth $123M.
- Tang Capital Management added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $8.08M increase.
- Tang Capital Management's biggest Q2 2021 reduction was Relmada Therapeutics, cutting an estimated $3.47M.
- Tang Capital Management fully exited Vincerx Pharma, Inc. Warrant in Q2 2021, selling an estimated $4.1M.
- Tang Capital Management's ten largest holdings make up 95% of its $502M portfolio in Q2 2021.
- Tang Capital Management opened 6 new positions and closed 1 in Q2 2021.
- Tang Capital Management's portfolio value rose 41% quarter-over-quarter to $502M.
Based on Tang Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.